about
Detection of EpCAM-positive microparticles in pleural fluid: A new approach to mini-invasively identify patients with malignant pleural effusions.Malignant pleural mesothelioma: from the bench to the bedside.Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.Effects of CPAP on systemic hypertension in OSAH: a monocentric, observational, cohort study.MANAGEMENT OF ENDOCRINE DISEASE: RISK OF OVERTREATMENT OF PATIENTS WITH ADRENAL INSUFFICIENCY: CURRENT AND EMERGING ASPECTS.Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?Echocardiographic evaluation in subjects with α1-Antitrypsin deficiency.18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension.Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis.Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.Elastic properties of the ascending aorta in patients with α1-antitrypsin deficiency (Z homozygotes).Positive FDG-PET/CT of the pleura twenty years after talc pleurodesis: three cases of benign talcoma.Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy.Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues.Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practiceIFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug?Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcomaRegression of advanced neuroendocrine tumors among patients receiving placeboPositive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusionsPalbociclib inhibits proliferation of human adrenocortical tumor cellsMorphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional studyWhen Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs)Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective StudyDecision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management optionsOutcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional caseAbiraterone acetate exerts a cytotoxic effect in human prostate cancer cell linesMaintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial
P50
Q36772138-207FAD4F-5BDF-4259-908C-710445D6CB6CQ38019747-48AEF13A-44E9-4076-95B6-3E3E32B9FB40Q38825846-F1450C73-2C86-4758-A3C2-8BD582224980Q38966901-58137B07-B245-4A32-9BD4-FF85FD866B29Q39202898-12B79321-E01D-4493-A5CA-C9D3CB93CC6DQ39353087-3C9A37A0-1B6F-4A00-A15F-B4178C75EA1FQ40947282-EA9B3611-07EF-4DBC-BA70-86EBEBAD6AA6Q41499507-B4C67F8E-3563-4677-9AD5-E7AC6767DD94Q43623082-CC19B8FD-F60A-447C-826D-B46561754AD6Q47253056-1F8F75A5-030E-484E-98A5-A77CE7EED462Q48190874-8C194231-4370-4985-B6EA-9824A9EA2FD1Q49897949-3C96F4AB-518E-4327-96B8-FF61FC509DA4Q50091898-129C8653-E16D-4D0C-A473-85A9663F4D5EQ51321183-FD65909C-0C16-40AF-83EA-24B1F13B0400Q53082277-D0BE3842-71B0-4868-BAC9-E02F4FBCF5C5Q53099218-F386EEE4-6123-40A4-81CA-ED4EC89BABEAQ53729565-1FA13270-3B40-4711-AEFC-153BFD0A4B79Q54053314-B809E9BF-01DA-4D06-9F52-92176D24C302Q58127676-89823321-5589-4A58-8F41-771A328AF1DCQ88024302-D09972B1-BF0D-4D38-BC47-0B39435CB875Q88076220-22AF4536-6788-45DF-A9F9-F6D110B930ADQ88970001-DAD12CC9-D8AE-4D71-8FD6-9190F58D9D3AQ89379583-442BEE59-B15F-497B-8121-EE36B429BEDEQ89424034-7B3C0CFE-60B3-4DC0-9207-77A95311B11BQ89916393-2F4763E6-7F2A-4485-9142-0147ABBDCF6AQ89942596-10A9568C-CBD3-4CB1-9963-920BD33636C1Q90345998-D1A9DC9F-3372-4AAE-AC55-B4C3BDE0109BQ90418620-7936E0C5-FA20-4FDC-95E1-85322DE09508Q90998574-C1746DC7-CDD7-4613-83D9-1DD62864542DQ91043004-4B10790D-00BB-47DA-99D0-FEBCFA051859Q91637730-4FCE2C7A-2CDC-4C03-BDFC-066C43743154Q91997809-E7753B1F-F587-4781-ACA0-6DD818C5E8EC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisa Roca
@ast
Elisa Roca
@en
Elisa Roca
@es
Elisa Roca
@nl
Elisa Roca
@sl
type
label
Elisa Roca
@ast
Elisa Roca
@en
Elisa Roca
@es
Elisa Roca
@nl
Elisa Roca
@sl
prefLabel
Elisa Roca
@ast
Elisa Roca
@en
Elisa Roca
@es
Elisa Roca
@nl
Elisa Roca
@sl
P106
P1153
55259921100
P21
P31
P496
0000-0001-7625-7708